Known targets — ChEMBL curated mechanism
ACEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ATP4AATP4BAXLBTKCACNA1CCACNA1DCACNA1FCACNA1SCCR5CHRM2CHRM3CPT1BCPT2DPP4DRD1DRD2EGFRERBB2ERBB4FLT3HRH1HRH3HTR1AHTR2AHTR2BHTR2CHTR4JAK1JAK2JAK3KCNH2KMT2AMAP2K1MAP2K2MEN1MLNRMPLMTORPPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PLK4PPARGRENS1PR1SLC6A2SLC6A3SLC6A4SMOTYK2atpAatpBatpCatpDatpEatpFatpFHatpGpol
The experimentally established mechanism targets of Fumaric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR4 | P46093 | 4/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fumaric Acid SCHEMBL6046514 | 1.00 | GPR4 (0.69) | GPR4 | |
| SCHEMBL6046532 | 0.93 | GPR4 (0.78) | GPR4 | |
| SCHEMBL6046535 | 0.85 | GPR4 (0.71) | GPR4 | |
| SCHEMBL6046452 | 0.84 | GPR4 (0.73) | GPR4 | |
| SCHEMBL6046468 | 0.83 | GPR4 (0.98) | GPR4 | |
| SCHEMBL13634003 | 0.81 | GPR4 (0.58) | GPR4 | |
| SCHEMBL6046454 | 0.81 | GPR4 (0.70) | GPR4 | |
| SCHEMBL6046464 | 0.80 | GPR4 (0.76) | GPR4 | |
| SCHEMBL6046526 | 0.80 | GPR4 (1.00) | GPR4 | |
| SCHEMBL6046480 | 0.79 | GPR4 (0.75) | GPR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060252679-A1 | Preventive and/or trerapeutic drgs for itch | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2006-11-09 | — | — | US | disclosed |
| US-20060239999-A1 | Preventive and/or therapeutic drugs for asthma | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2006-10-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060239999-A1 | Preventive and/or therapeutic drugs for asthma | GPR4, HRH4, GPR3 | GPR4 1/4885 |
| US-20060252679-A1 | Preventive and/or trerapeutic drgs for itch | GPR4, TRPV1, TRPV4 | GPR4 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.